<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00518362</url>
  </required_header>
  <id_info>
    <org_study_id>NJCT-0701</org_study_id>
    <nct_id>NCT00518362</nct_id>
  </id_info>
  <brief_title>To Compare the Efficacy and Safety of Tripterygium (TW) Versus Valsartan in the Diabetic Nephropathy (DN)</brief_title>
  <official_title>To Compare the Efficacy and Safety of TW vs Valsartan in the DN</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanjing University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanjing University School of Medicine</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the efficacy and safety of Tripterygium (TW) versus
      Valsartan (ARB) in the Diabetic Nephropathy (DN).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diabetic nephropathy with heavy proteinuria have high risks of progressing to end stage renal
      disease. Though recent studies have shown that ACEI or ARB could reduce proteinuria of DN and
      slowed the progression to ESRD. But ARBs can only reduce proteinuria about 30%, so some
      patients still have heavy proteinuria,and then loss their renal function rapidly. So, to
      reduce the proteinuria of DN is a very important therapy target.

      Tripterygium (TW) is a Chinese traditional patent drug, it can reduce proteinuria of chronic
      glomerular nephritis. So, we designed this randomized, prospective clinical trial to assess
      the efficacy and safety of TW versus ARB in the treatment of heavy proteinuria of DN.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2007</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">September 2009</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To access the efficacy of TW compared to ARB in treatment of heavy proteinuria of diabetic nephropathy</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To investigate the safety and tolerability of TW vs ARB. To access whether TW can delay the progression to ESRD or creatinine-doubling in diabetic nephropathy with heavy proteinuria.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">67</enrollment>
  <condition>Diabetic Nephropathy</condition>
  <arm_group>
    <arm_group_label>immunosuppressor</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Valsartan,160mg/d,TW 120mg/d</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TW</intervention_name>
    <description>TW,120 mg/d</description>
    <arm_group_label>immunosuppressor</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. A new diagnosis of diabetic nephropathy proved by histology and(or) serology.

          2. Proteinuria &gt; 2.5 g/24 h

          3. serum creatinine &lt; 3 mg/dl

          4. age 35-65 years

        Exclusion Criteria:

          1. Co-existence of anther chronic glomerular nephritis.

          2. Severe disfunction of the liver

          3. White blood cell &lt; 3000/ul

          4. Severe infection in the past 1 month

          5. Malignant hypertension which in hard to control

          6. Myocardial infarct or heart failure or sever cerebral vessels complication in the past
             6 month
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>35 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Zhihong Liu, Master</last_name>
    <role>Principal Investigator</role>
    <affiliation>Jinling Hospital, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Institute of Nephrology</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210002</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>April 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>August 16, 2007</study_first_submitted>
  <study_first_submitted_qc>August 16, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 20, 2007</study_first_posted>
  <last_update_submitted>May 25, 2010</last_update_submitted>
  <last_update_submitted_qc>May 25, 2010</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 27, 2010</last_update_posted>
  <responsible_party>
    <name_title>Research Institute of Nephrology, Jinling Hospital, Nanjing University School of Medicine</name_title>
    <organization>Nanjing University School of Medicine</organization>
  </responsible_party>
  <keyword>TW</keyword>
  <keyword>Valsartan</keyword>
  <keyword>treatment</keyword>
  <keyword>diabetic nephropathy</keyword>
  <keyword>Proteinuria</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Diabetic Nephropathies</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

